News
12-12-2010, 11:31 PM
Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.
More... (http://www.news-medical.net/news/20101213/Phase-III-study-shows-comparison-of-lapatinib-and-trastuzumab-with-chemotherapy-for-early-breast-cancer-patients.aspx)
More... (http://www.news-medical.net/news/20101213/Phase-III-study-shows-comparison-of-lapatinib-and-trastuzumab-with-chemotherapy-for-early-breast-cancer-patients.aspx)